The CARI guidelines. Prevention of progression of kidney disease

Nephrology (Carlton). 2006 Apr:11 Suppl 1:S2-197. doi: 10.1111/j.1440-1797.2006.00505.x.
No abstract available

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acidosis / therapy
  • Adult
  • Analgesics / adverse effects
  • Angiotensin II / antagonists & inhibitors
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Calcium Channel Blockers / therapeutic use
  • Child
  • Cyclosporine / therapeutic use
  • Diabetic Nephropathies / drug therapy
  • Diet, Protein-Restricted
  • Exercise
  • Female
  • Fish Oils / therapeutic use
  • Glomerulonephritis, IGA / therapy
  • Glomerulonephritis, Membranous / drug therapy
  • Glomerulonephritis, Membranous / therapy
  • Glomerulosclerosis, Focal Segmental / drug therapy
  • Glomerulosclerosis, Focal Segmental / therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertension / drug therapy
  • Hypertension / prevention & control
  • Hyperuricemia / therapy
  • Kidney Diseases / diet therapy
  • Kidney Diseases / prevention & control*
  • Kidney Diseases / therapy
  • Kidney Failure, Chronic / prevention & control
  • Phosphates / metabolism
  • Pregnancy
  • Pregnancy Complications / therapy
  • Proteinuria / drug therapy
  • Renal Artery Obstruction / therapy
  • Smoking Cessation
  • Tonsillectomy

Substances

  • Analgesics
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Fish Oils
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Phosphates
  • Angiotensin II
  • Cyclosporine